GFAP and myeloid sarcoma: Moreover, in a cohort study on multiple sclerosis (MS), serum GFAP levels failed to predict disease activity and progression, whereas CSF GFAP levels were significant predictors despite a correlation existing between CSF and serum GFAP levels and other glial/neuroinflammation markers [12].